Designing effective vaccines for colorectal cancer

Immunotherapy

Volumn 6, Issue 8, 2014, Pages 913-926

  Patel, Sandip P ^a   Osada, Takuya ^b   Lyerly, H Kim ^c   Morse, Michael A ^c  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

colon cancer; colorectal cancer; dendritic cell; immune infiltrate; immunotherapy; mCRC; T cell; tumor microenvironment; tumor vaccine; vaccine

Indexed keywords

ANTIIDIOTYPIC ANTIBODY; CANCER VACCINE; FALIMAREV; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; PEPTIDE VACCINE; PEPTIDE;

ANTIBODY RESPONSE; ANTIGEN PRESENTATION; CANCER CONTROL; CANCER IMMUNOTHERAPY; COLORECTAL CANCER; DRUG DESIGN; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOGENICITY; LYMPH NODE; METASTATIC COLORECTAL CANCER; POPULATION; REVIEW; T LYMPHOCYTE; TUMOR MICROENVIRONMENT; COLORECTAL NEOPLASMS;

CANCER VACCINES; COLORECTAL NEOPLASMS; DRUG DESIGN; HUMANS; PEPTIDES;

EID: 84907940568     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.14.61     Document Type: Review

References (103)

1. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350, 2335-2342 (2004
2. Chu E. An update on the current and emerging targeted agents in metastatic colorectal cancer. Clin. Colorectal Cancer 11(1), 1-13 (2012
3. Rosenberg SA, Yang JC, Topalian SL et al. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA 271(12), 907-913 (1994
4. Osada T, Hsu D, Hammond S et al. Metastatic colorectal cancer cells from patients previously treated with chemotherapy are sensitive to T cell killing mediated by CEA/CD3-bispecific T cell-engaging BiTE antibody. Br. J. Cancer 102(1), 124-133 (2009
5. Pagès F, Galon J, Dieu-Nosjean M-C, Tartour E, Sautès- Fridman C, Fridman W-H. Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene 29, 1093-1102 (2010
6. Ferrone C, Dranoff G. Dual roles for immunity in gastrointestinal cancers. J. Clin. Oncol. 28(26), 4045-4051 (2010
7. Boghossian S, Robinson S, Von Delwig A, Manas D, White S. Immunotherapy for treating metastatic colorectal cancer. Surg. Oncol. 21(2), 67-77 (2012
8. Ellebaek E, Andersen MH, Svane IM, Straten PT. Immunotherapy for metastatic colorectal cancer: present status and new options. Scand. J. Gastroenterol. 47(3), 315-324 (2012
9. Conrad C, Gregorio J, Wang Y-H et al. Plasmacytoid dendritic cells promote immunosuppression in ovarian cancer via ICOS costimulation of Foxp3+ T-regulatory cells. Cancer Res. 72(20), 5240-5249 (2012
10. Tel J, Schreibelt G, Sittig SP et al. Human plasmacytoid dendritic cells efficiently cross-present exogenous Ags to CD8+ T cells despite lower Ag uptake than myeloid dendritic cell subsets. Blood 121(3), 459-467 (2013
11. Tel J, Aarntzen EHJG, Baba T et al. Natural human plasmacytoid dendritic cells induce antigen-specific T cell responses in melanoma patients. Cancer Res. 73(3), 1063-1075 (2013
12. Goyvaerts C, Kurt DG, Lint SV et al. Immunogenicity of targeted lentivectors. Oncotarget 5(3), 704-715( 2014
13. Tosolini M, Kirilovsky A, Mlecnik B et al. Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, Th2, Treg, Th17) in patients with colorectal cancer. Cancer Res. 71(4), 1263-1271 (2011
14. Terhune J, Berk E, Czerniecki B. Dendritic cell-induced Th1 and Th17 cell differentiation for cancer therapy. Vaccines 1(4), 527-549 (2013
15. Schreck S, Friebel D, Buettner M et al. Prognostic impact of tumour-infiltrating Th2 and regulatory T cells in classical Hodgkin lymphoma. Hematolog. Oncol. 27(1), 31-39 (2009
16. Sawant A, Hensel JA, Chanda D et al. Depletion of plasmacytoid dendritic cells inhibits tumor growth and prevents bone metastasis of breast cancer cells. J. Immunol. 189(9), 4258-4265 (2012
17. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 331(6024), 1565-1570 (2011
18. Merika E, Saif M, Katz A, Syrigos C, Morse M. Colon cancer vaccines: an update. In Vivo 24(5), 607-628 (2010
19. Ogino S, Nosho K, Irahara N et al. Lymphocytic reaction to colorectal cancer is associated with longer survival, independent of lymph node count, microsatellite instability, and CpG island methylator phenotype. Clin. Cancer Res. 15(20), 6412-6420 (2009
20. Pagès F, Berger A, Camus M et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N. Engl. J. Med. 353(25), 2654-2666 (2005
21. Coca S, Perez-Piqueras J, Martinez D et al. The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma. Cancer 79(12), 2320-2328 (1997
22. Salama P, Phillips M, Grieu F et al. Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. J. Clin. Oncol. 27, 186-192 (2009
23. Whiteside TL, Schuler P, Schilling B. Induced and natural regulatory T cells in human cancer. Expert Opin. Bio. Ther. 12, 1383-1397 (2012
24. Ladoire S, Martin F, Ghiringhelli F. Prognostic role of FOXP3+ regulatory T cells infiltrating human carcinomas: the paradox of colorectal cancer. Cancer Immunol. Immunother. 60(7), 909-918 (2011
25. Keerthivasan S, Aghajani K, Dose M et al. ?-catenin promotes colitis and colon cancer through imprinting of proinflammatory properties in T cells. Sci. Transl. Med. 6(225), 225ra228 (2014
26. Kuniyasu H, Sasaki T, Sasahira T, Ohmori H, Takahashi T. Depletion of tumor-infiltrating macrophages is associated with amphoterin expression in colon cancer. Pathobiology 71(3), 129-136 (2004
27. Etoh T, Shibuta K, Barnard GF, Kitano S, Mori M. Angiogenin expression in human colorectal cancer: the role of focal macrophage infiltration. Clin. Cancer Res. 6(9), 3545-3551 (2000
28. Nagorsen D, Voigt S, Berg E, Stein H, Thiel E, Loddenkemper C. Tumor-infiltrating macrophages and dendritic cells in human colorectal cancer: relation to local regulatory T cells, systemic T cell response against tumor-associated antigens and survival. J. Transl. Med. 5(62), 52-60 (2007
29. Sandel MH, Dadabayev AR, Menon AG et al. Prognostic value of tumor-infiltrating dendritic cells in colorectal cancer: role of maturation status and intratumoral localization. Clin. Cancer Res. 11(7), 2576-2582 (2005
30. Brandacher G, Perathoner A, Ladurner R et al. Prognostic value of indoleamine 2, 3-dioxygenase expression in colorectal cancer: effect on tumor-infiltrating T cells. Clin. Cancer Res. 12(4), 1144-1151 (2006
31. Ahmadzadeh M, Rosenberg SA. TGF-?1 attenuates the acquisition and expression of effector function by tumor antigen-specific human memory CD8 T cells. J. Immunol. 174(9), 5215-5223 (2005
32. Nemunaitis J, Dillman RO, Schwarzenberger PO et al. Phase I study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer. J. Clin. Oncol. 24(29), 4721-4730 (2006
33. Narai S, Watanabe M, Hasegawa H et al. Significance of transforming growth factor ?1 as a new tumor marker for colorectal cancer. Int. J. Cancer 97(4), 508-511 (2002
34. Galizia G, Orditura M, Romano C et al. Prognostic significance of circulating IL-10 and IL-6 serum levels in colon cancer patients undergoing surgery. Clin. Immunol. 102(2), 169-178 (2002
35. Rosenberg SA, Lotze MT, Yang JC et al. Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer. J. Clin. Oncol. 7(12), 1863-1874 (1989
36. Wiesenfeld M, O'Connell MJ, Wieand HS et al. Controlled clinical trial of interferon-gamma as postoperative surgical adjuvant therapy for colon cancer. J. Clin. Oncol. 13(9), 2324-2329 (1995
37. Wolmark N, Smith R, Fisher B et al. Adjuvant 5-fluorouracil and leucovorin with or without interferon alfa-2a in colon carcinoma: National Surgical Adjuvant Breast and Bowel Project protocol C-05. J. Natl Cancer Inst. 90(23), 1810-1816 (1998
38. Panettiere FJ, Goodman PJ, Costanzi JJ et al. Adjuvant therapy in large bowel adenocarcinoma: long-term results of a Southwest Oncology Group Study. J. Clin. Oncol. 6(6), 947-954 (1988
39. Smith RE, Colangelo L, Wieand HS, Begovic M, Wolmark N. Randomized trial of adjuvant therapy in colon carcinoma: 10-year results of NSABP protocol C-01. J. Natl Cancer Inst. 96(15), 1128-1132 (2004
40. Patel SP, Osada T, Osada K, Hurwitz H, Lyerly HK, Morse MA. Modulation of immune system inhibitory checkpoints in colorectal cancer. Curr. Colorectal Cancer Reports 9(4), 391-397 (2013
41. Harris JE, Ryan L, Hoover HC et al. Adjuvant active specific immunotherapy for stage II and III colon cancer with an autologous tumor cell vaccine: Eastern Cooperative Oncology Group Study E5283. J. Clin. Oncol. 18(1), 148-148 (2000
42. Vermorken JB, Claessen AM, Van Tinteren H et al. Active specific immunotherapy for stage II and Stage III human colon cancer: a randomised trial. Lancet 353(9150), 345-350 (1999
43. Schulze T, Kemmner W, Weitz J, Wernecke K-D, Schirrmacher V, Schlag P. Efficiency of adjuvant active specific immunization with Newcastle disease virus modified tumor cells in colorectal cancer patients following resection of liver metastases: results of a prospective randomized trial. Cancer Immunol. Immunother. 58(1), 61-69 (2009
44. Rao B, Han M, Wang L et al. Clinical outcomes of active specific immunotherapy in advanced colorectal cancer and suspected minimal residual colorectal cancer: a meta-analysis and system review. J. Transl. Med. 9(1), 17-28 (2011
45. De Weger VA, Turksma AW, Voorham QJM et al. Clinical effects of adjuvant active specific immunotherapy differ between patients with microsatellite-stable and microsatelliteinstable colon cancer. Clin. Cancer Res. 18(3), 882-889 (2012
46. Goldman B, Defrancesco L. The cancer vaccine roller coaster. Nat. Biotech. 27(2), 129-139 (2009
47. Staff C, Mozaffari F, Haller BK, Wahren B, Liljefors M. A Phase I safety study of plasmid DNA immunization targeting carcinoembryonic antigen in colorectal cancer patients. Vaccine 29(39), 6817-6822 (2011
48. Hörig H, Lee DS, Conkright W et al. Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7. 1 co-stimulatory molecule. Cancer Immunol. Immunother. 49(9), 504-514 (2000
49. Marshall JL, Hawkins MJ, Tsang KY et al. Phase I study in cancer patients of a replication-defective Avipox recombinant vaccine that expresses human carcinoembryonic antigen. J. Clin. Oncol. 17(1), 332-338 (1999
50. Kaufman HL, Lenz H-J, Marshall J et al. Combination chemotherapy and ALVAC-CEA/B7.1 vaccine in patients with metastatic colorectal cancer. Clin. Cancer Res. 14(15), 4843-4849 (2008
51. Hodge JW, Mclaughlin JP, Kantor JA, Schlom J. Diversified prime and boost protocols using recombinant vaccinia virus and recombinant non-replicating avian pox virus to enhance T cell immunity and antitumor responses. Vaccine 15(6-7), 759-768 (1997
52. Morse MA, Hobeika AC, Osada T et al. An alphavirus vector overcomes the presence of neutralizing antibodies and elevated numbers of Tregs to induce immune responses in humans with advanced cancer. J. Clin. Inv. 120(9), 3234-3241 (2010
53. Kimura T, Mckolanis JR, Dzubinski LA et al. MUC1 vaccine for individuals with advanced adenoma of the colon: a Cancer Immunoprevention Feasibility Study. Cancer Prev. Res. 6(1), 18-26 (2013
54. Moulton HM, Yoshihara PH, Mason DH, Iversen PL, Triozzi PL. Active specific immunotherapy with a ?-human chorionic gonadotropin peptide vaccine in patients with metastatic colorectal cancer: antibody response is associated with improved survival. Clin. Cancer Res. 8(7), 2044-2051 (2002
55. Morse MA, Chapman R, Powderly J et al. Phase I study utilizing a novel antigen-presenting cell-targeted vaccine with Toll-like receptor stimulation to induce immunity to self-antigens in cancer patients. Clin. Cancer Res. 17(14), 4844-4853 (2011
56. Went P, Vasei M, Bubendorf L et al. Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers. Briti. J. Cancer 94(1), 128-135 (2006
57. Ullenhag GJ, Frödin J-E, Mosolits S et al. Immunization of colorectal carcinoma patients with a recombinant canarypox virus expressing the tumor antigen Ep-CAM/KSA (ALVACKSA) and granulocyte macrophage colony-stimulating factor induced a tumor-specific cellular immune response. Clin. Cancer Res. 9(7), 2447-2456 (2003
58. Van Der Burg SH, Menon AG, Redeker A et al. Induction of p53-specific immune responses in colorectal cancer patients receiving a recombinant ALVAC-p53 candidate vaccine. Clin. Cancer Res. 8(5), 1019-1027 (2002
59. Speetjens FM, Kuppen PJ, Welters MJ et al. Induction of p53- specific immunity by a p53 synthetic long peptide vaccine in patients treated for metastatic colorectal cancer. Clin. Cancer Res. 15(3), 1086-1095 (2009
60. Zeestraten E, Speetjens FM, Welters MJ et al. Addition of interferon-? to the p53-SLP® vaccine results in increased production of interferon-? in vaccinated colorectal cancer patients: a Phase I/II clinical trial. Int. J. Cancer 132(7), 1581-1591 (2013
61. Lima CR, Buck R, Meyer K, Mitrica I, Perkins W, Michaeli D. A multicenter Phase II study of irinotecan in combination with G17DT immunogen in subjects with metastatic colorectal adenocarcinoma (CRC) refractory to previous irinotecan-based chemotherapy. J. Clin. Oncol. 22(14S), 3573 (2004
62. Harrop R, Shingler W, Kelleher M, De Belin J, Treasure P. Cross-trial analysis of immunologic and clinical data resulting from Phase I and II trials of MVA-5T4 (TroVax) in colorectal, renal, and prostate cancer patients. J. Immunother.33(9), 999-1005 (2010
63. Amato RJ, Stepankiw M. Evaluation of MVA-5T4 as a novel immunotherapeutic vaccine in colorectal, renal and prostate cancer. Future Oncol. 8(3), 231-237 (2012
64. Harrop R, Treasure P, Belin J et al. Analysis of pre-treatment markers predictive of treatment benefit for the therapeutic cancer vaccine MVA-5T4 (TroVax). Cancer Immunol. Immunother. 61(12), 2283-2294 (2012
65. Tsuruma T, Hata F, Torigoe T et al. Phase I clinical study of anti-apoptosis protein, survivin-derived peptide vaccine therapy for patients with advanced or recurrent colorectal cancer. J. Trans. Med. 2(1), 19-30 (2004
66. Miyagi Y, Imai N, Sasatomi T et al. Induction of cellular immune responses to tumor cells and peptides in colorectal cancer patients by vaccination with SART3 peptides. Clin. Cancer Res. 7(12), 3950-3962 (2001
67. Inoda S, Morita R, Hirohashi Y et al. The feasibility of Cep55/c10orf3 derived peptide vaccine therapy for colorectal carcinoma. Exp. Mol. Pathol. 90(1), 55-60 (2011
68. Castle JC, Kreiter S, Diekmann J et al. Exploiting the mutanome for tumor vaccination. Cancer Res. 72(5), 1081-1091 (2012
69. Casimiro DR, Chen L, Fu T-M et al. Comparative immunogenicity in rhesus monkeys of DNA plasmid, recombinant vaccinia virus, and replication-defective adenovirus vectors expressing a human immunodeficiency virus Type I gag gene. J. Virol. 77(11), 6305-6313 (2003
70. Mcconkey SJ, Reece WHH, Moorthy VS et al. Enhanced T cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat. Med. 9(6), 729-735 (2003
71. Abès R, Teillaud J-L. Modulation of tumor immunity by therapeutic monoclonal antibodies. Cancer Metast. Rev. 30(1), 111-124 (2011
72. Foon KA, John WJ, Chakraborty M et al. Clinical and immune responses in resected colon cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen. J. Clin. Oncol. 17(9), 2889-2896(1999
73. Chong G, Bhatnagar A, Cunningham D et al. Phase III trial of 5-fluorouracil and leucovorin plus either 3H1 anti-idiotype monoclonal antibody or placebo in patients with advanced colorectal cancer. Annals Oncol. 17(3), 437-442 (2006
74. Posner M, Niedzwiecki D, Venook A et al. A Phase II prospective multi-institutional trial of adjuvant active specific immunotherapy following curative resection of colorectal cancer hepatic metastases: cancer and leukemia Group B Study 89903. Ann. Surg. Oncol. 15(1), 158-164 (2008
75. Spendlove I, Ramage JM, Bradley R, Harris C, Durrant LG. Complement decay accelerating factor (DAF)/CD55 in cancer. Cancer Immunol. Immunother. 55(8), 987-995 (2006
76. Ullenhag GJ, Spendlove I, Watson NF et al. A neoadjuvant/adjuvant randomized trial of colorectal cancer patients vaccinated with an anti-idiotypic antibody, 105AD7, mimicking CD55. Clin. Cancer Res. 12(24), 7389-7396 (2006
77. Maxwell-Armstrong C, Durrant L, Buckley T et al. Randomized double-blind Phase II survival study comparing immunization with the anti-idiotypic monoclonal antibody 105AD7 against placebo in advanced colorectal cancer. Brit. J. Cancer 84(11), 1443-1446 (2001
78. Samonigg H, Wilders-Truschnig M, Kuss I et al. A doubleblind randomized-Phase II trial comparing immunization with antiidiotype goat antibody vaccine SCV 106 versus unspecific goat antibodies in patients with metastatic colorectal cancer. J. Immunother. 22(6), 482-488 (1999
79. Verma S, Miles D, Gianni L et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N. Engl. J. Med. 367, 1783-1791 (2012
80. Klinger M, Brandl C, Zugmaier G et al. Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab. Blood 119, 6226-6233 (2012
81. Cheever MA, Higano CS. PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine. Clin. Cancer Res. 17(11), 3520-3526 (2011
82. Kantoff PW, Higano CS, Shore ND et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363, 411-422 (2010
83. Tamir A, Basagila E, Kagahzian A et al. Induction of tumor-specific T cell responses by vaccination with tumor lysate-loaded dendritic cells in colorectal cancer patients with carcinoembryonic-antigen positive tumors. Cancer Immunol. Immunother. 56(12), 2003-2016 (2007
84. Wu Y-G, Wu G-Z, Wang L, Zhang Y-Y, Li Z, Li D-C. Tumor cell lysate-pulsed dendritic cells induce a T cell response against colon cancer in vitro and In vivo. Med. Oncol. 27(3), 736-742 (2010
85. Liu Y, Zhang W, Zhang B, Yin X, Pang Y. DC vaccine therapy combined concurrently with oral capecitabine in metastatic colorectal cancer patients. Hepato-Gastroenterol. 60(121), 23-27 (2013
86. Burgdorf SK, Fischer A, Myschetzky PS et al. Clinical responses in patients with advanced colorectal cancer to a dendritic cell based vaccine. Oncol. Reports 20(6), 1305-1311 (2008
87. Toh HC, Wang W-W, Chia WK et al. Clinical benefit of allogeneic melanoma cell lysate-pulsed autologous dendritic cell vaccine in MAGE-positive colorectal cancer patients. Clin. Cancer Res. 15(24), 7726-7736 (2009
88. Barth RJ, Fisher DA, Wallace PK et al. A randomized trial of ex vivo CD40L activation of a dendritic cell vaccine in colorectal cancer patients: tumor-specific immune responses are associated with improved survival. Clin. Cancer Res. 16(22), 5548-5556 (2010
89. Nair SK, Morse M, Boczkowski D et al. Induction of tumor-specific cytotoxic T lymphocytes in cancer patients by autologous tumor RNA-transfected dendritic cells. Annals. Surg. 235(4), 540-549 (2002
90. Lesterhuis WJ, De Vries IJM, Schuurhuis DH et al. Vaccination of colorectal cancer patients with CEA-loaded dendritic cells: antigen-specific T cell responses in DTH skin tests. Annals Oncol. 17(6), 974-980 (2006
91. Lesterhuis WJ, De Vries IJM, Aarntzen EA et al. A pilot study on the immunogenicity of dendritic cell vaccination during adjuvant oxaliplatin/capecitabine chemotherapy in colon cancer patients. Br. J. Cancer 103(9), 1415-1421 (2010
92. Kavanagh B, Ko A, Venook A et al. Vaccination of metastatic colorectal cancer patients with matured dendritic cells loaded with multiple major histocompatibility complex class I peptides. J. Immunother. 30(7), 762-772 (2007
93. Morse MA, Nair S, Fernandez-Casal M et al. Preoperative mobilization of circulating dendritic cells by Flt3 ligand administration to patients with metastatic colon cancer. J. Clin. Oncol. 18(23), 3883-3893 (2000
94. Fong L, Hou Y, Rivas A et al. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Natl Acad. Sci. 98(15), 8809-8814 (2001
95. Liu K-J, Wang C-C, Chen L-T et al. Generation of carcinoembryonic antigen (CEA)-specific T cell responses in HLA-A. 0201 and HLA-A. 2402 late-stage colorectal cancer patients after vaccination with dendritic cells loaded with CEA peptides. Clin. Cancer Res. 10(8), 2645-2651 (2004
96. Babatz J, Röllig C, Löbel B et al. Induction of cellular immune responses against carcinoembryonic antigen in patients with metastatic tumors after vaccination with altered peptide ligand-loaded dendritic cells. Cancer Immunol. Immunother. 55(3), 268-276 (2006
97. Morse MA, Clay TM, Hobeika AC et al. Phase I study of immunization with dendritic cells modified with Fowlpox encoding carcinoembryonic antigen and costimulatory molecules. Clin. Cancer Res. 11(8), 3017-3024 (2005
98. Morse MA, Niedzwiecki D, Marshall JL et al. A randomized Phase II study of immunization with dendritic cells modified with poxvectors encoding CEA and MUC1 compared with the same poxvectors plus GM-CSF for resected metastatic colorectal cancer. Annal. Surg. 258(6), 879-886 (2013
99. Hodi FS, O' Day SJ, Mcdermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Eng. J. Med. 363, 711-723 (2010
100. Weber JS, Ka KC. Management of immune-related adverse events and kinetics of response with ipilimumab. 30, 2691-2697 (2012
101. Nagorsen D, Thiel E. Clinical and immunologic responses to active specific cancer vaccines in human colorectal cancer. Clin. Cancer Res. 12(10), 3064-3069 (2006
102. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N. Engl. J. Med. 365(8), 725-733 (2011
103. Davila ML, Riviere I, Wang X et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Science Trans. Med. 6(224), 224ra225 (2014